Logo CICANCER
Intranet Colaborate

Old CIC Events

In search of the ideal Trojan horse for antitumor treatments 09/06/2026

In search of the ideal Trojan horse for antitumor treatments

Pilar Martín-Duque — Instituto de Salud Carlos lll, Departamento de Desarrollo de Medicamentos y Terapias Avanzadas (DDMTAs)

The therapeutic targeting of epitranscriptome-associated proteins 04/06/2026

The therapeutic targeting of epitranscriptome-associated proteins

Konstantinos Tzelepis — Cambridge Stem Cell Institute, University of Cambridge

Metabolic crosstalk between the tumour and the host 28/05/2026

Metabolic crosstalk between the tumour and the host

Karen Vousden — Francis Crick Institute, UK

Role of the repressor Capicua in KRAS-driven lung tumor development. 14/05/2026

Role of the repressor Capicua in KRAS-driven lung tumor development.

Irene Ballesteros González — Centro de Investigación del Cáncer (CSIC, USAL, FICUS)

Drug-mediated kinase activation: A new type of chemotherapy to target therapy-resistant cancer cells 07/05/2026

Drug-mediated kinase activation: A new type of chemotherapy to target therapy-resistant cancer cells

Óscar Fernández-Capetillo — CNIO-Instituto Karolinska, Sweden

A portfolio of immunotherapies to treat ALK+ cancers 30/04/2026

A portfolio of immunotherapies to treat ALK+ cancers

Roberto Chiarle — Department of Pathology (Boston Children's Hospital)

Evaluating Next-Generation CAR-T Cells in Complex Tumor-Immune Models 28/04/2026

Evaluating Next-Generation CAR-T Cells in Complex Tumor-Immune Models

Naiara Martínez-Vélez — Stanford University

Defensa de tesis doctoral: C3G in chronic myeloid leukemia: linking disease progression in mouse models with cellular leukemogenic mechanisms 17/04/2026

Defensa de tesis doctoral: C3G in chronic myeloid leukemia: linking disease progression in mouse models with cellular leukemogenic mechanisms

Pablo Berrocal — Programa de Doctorado: Biología y Clínica del Cáncer

ZMYM3 and ZNF292 mutations in chronic lymphocytic leukemia: clinical and biological implications 16/04/2026

ZMYM3 and ZNF292 mutations in chronic lymphocytic leukemia: clinical and biological implications

Alberto Rodríguez Sánchez — Centro de Investigación del Cáncer (CSIC-Universidad de Salamanca)

Harnessing Post-Lactational Involution for Breast Cancer Prevention 09/04/2026

Harnessing Post-Lactational Involution for Breast Cancer Prevention

Manuel Jesús Pérez Baena — Centro de Investigación del Cáncer (CSIC-USAL-FICUS)

Fluorescence imaging of lipid trafficking pipelines in mammalian cells 19/03/2026

Fluorescence imaging of lipid trafficking pipelines in mammalian cells

Juan Manuel Iglesias Artola — Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Germany

Defensa de tesis doctoral: Papel de la señalización RAS–PI3K en la regulación del fenotipo y la función de los fibroblastos asociados a cáncer 13/03/2026

Defensa de tesis doctoral: Papel de la señalización RAS–PI3K en la regulación del fenotipo y la función de los fibroblastos asociados a cáncer

Marta Alcón Pérez — Programa de doctorado Biología y Clínica del Cáncer